FDA approves Novartis Afinitor to treat advanced breast cancer Pharmaceutical Business Review Novartis has won FDA approval for Afinitor (everolimus) tablets for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ breast cancer) in combination with exemestane after failure ... |